Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia
Results from the first study from two large Saudi Arabian tertiary centers for patients with severe asthma and chronic rhinosinusitis agree with and support those of worldwide real-life ones. One-year follow-up of patients with SA and CRS showed the effectiveness of benralizumab and dupilumab, but not omalizumab, regarding FEV1, serum IgE, and eosinophilic counts. Further prospective multicenter studies are warranted.
Authors
- Bader I. Asiri
- Saad M. Alqahtani (ORCID: https://orcid.org/0000-0002-2198-7970)
- Abdullah Musleh (ORCID: https://orcid.org/0000-0003-2341-9552)
- Mohammed A. Alshehri
- Ali S. Kadasah
- Fawwaz A. Alshafa
- Medhat Elnamaky
- Salihah Y. Al-Mani (ORCID: https://orcid.org/0009-0006-1054-0053)
- Abdulmohsen Y. Assiri
- Usama Abu Elhassan
- Abdulrahman I. Falqi
- Saleem Alshehry
- Haneen A. Alasiri
- Abdulaziz Alfaifi
- Abdelrahman M. Abdalla
- Muhammad S. S. Qureshi
- Haider M. O. Ahmed
Institutions
- Armed Forces Hospital (SA)
- Armed Forces Hospital Southern Region
- King Khalid University (SA)
Publication Details
- Journal
- Multidisciplinary Respiratory Medicine
- Published
- 2024-09-09
- DOI
- https://doi.org/10.5826/mrm.2024.985
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.98